Tevogen Bio (NASDAQ:TVGN) Hits New 1-Year Low – Time to Sell?

Shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) hit a new 52-week low on Friday . The company traded as low as $6.2175 and last traded at $10.76, with a volume of 58999 shares. The stock had previously closed at $7.7550.

Analyst Ratings Changes

A number of equities research analysts have commented on TVGN shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Tevogen Bio in a report on Wednesday, January 21st. D. Boral Capital cut shares of Tevogen Bio from a “buy” rating to a “hold” rating in a research note on Wednesday. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Tevogen Bio currently has a consensus rating of “Reduce” and an average price target of $100.00.

Tevogen Bio Price Performance

The company has a market capitalization of $1.59 billion, a PE ratio of -42.16 and a beta of -0.76. The stock has a 50-day simple moving average of $0.30 and a 200 day simple moving average of $0.53.

Hedge Funds Weigh In On Tevogen Bio

Hedge funds have recently added to or reduced their stakes in the business. Bridgeway Capital Management LLC lifted its holdings in shares of Tevogen Bio by 66.7% in the third quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock valued at $65,000 after purchasing an additional 33,000 shares in the last quarter. Deutsche Bank AG raised its position in shares of Tevogen Bio by 304.1% during the 4th quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock worth $57,000 after purchasing an additional 130,738 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in shares of Tevogen Bio by 126.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock worth $91,000 after purchasing an additional 152,572 shares during the last quarter.

About Tevogen Bio

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.